|Bid||143.51 x 800|
|Ask||143.75 x 1200|
|Day's range||142.86 - 144.17|
|52-week range||109.16 - 157.00|
|Beta (5Y monthly)||0.69|
|PE ratio (TTM)||22.59|
|Earnings date||26 Jan 2021|
|Forward dividend & yield||4.04 (2.81%)|
|Ex-dividend date||23 Nov 2020|
|1y target est||166.18|
This basket of three dividend stocks contains an e-commerce leader and a potential coronavirus vaccine leader.
Score another pre-approval sale for coronavirus vaccine-maker Moderna (NASDAQ: MRNA). European Commission President Ursula von der Leyen has announced that the EC will ink a deal with the company on Wednesday. The contract will allow the European Union's member countries to purchase up to 160 million doses of Moderna's COVID-19 vaccine, mRNA-1273, once the vaccine is approved by EU regulators.
Interim data from late-stage studies on AstraZeneca (AZN) COVID-19 vaccine shows that the candidate was, on an average, about 70% effective in preventing COVID-19.